Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of… Read More »
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or… Read More »
ImmVira’s breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered… Read More »
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton’s tyrosine… Read More »
REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER
Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial H002 Has Potential To Overcome Resistance Driven By… Read More »
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboration and… Read More »
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment… Read More »
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
— Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden(Nyheter)(Nyheter), the Netherlands and Denmark(Nyheter)(Nyheter) Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted… Read More »
Rare Disease Day | With iCare, Love is Not Rare, MediTrust Health – iCare Clover Gives Care and Protection to Rare Disease Patients
“When Zixu was about 10 months old, he already seemed different from other children. He has curved fingers, a gradually… Read More »
Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced… Read More »